Preliminary results from the ongoing phase 2 clinical trial of ACE-083 in FSHD patients were presented today at the American Academy of Neurology 70th Annual Meeting in Los Angeles, California.The… Read More »
ACE-083 Phase 2 trial results presented at AAN conference
Intelligent orthotics step forward at the MIT Media Lab
During the 2014 biennial FSHD patient conference in Boston, the FSH Society arranged for a group to visit the MIT Media Laboratory, where Professor Hugh Herr leads a visionary team… Read More »
How the FSH Society drives FSHD therapy development
This infographic from our FY2017 Donor Report illustrates how the FSH Society is involved at every stage of the treatment development process. We invest strategically at key stages along the… Read More »
$133,254 awarded to FSHD Clinical Trials Research Network
The FSH Society has awarded a grant for a second year of support for the FSHD Clinical Trials Research Network (CTRN), through the coordinating center based at the University of… Read More »
FSH Society awards $690,894 in new research grants
A drug that helps muscles grow and regenerate. Molecules that occur naturally in our cells to repress DUX4, the “toxic gene” thought to cause FSHD. A deeper dive into why… Read More »